Cardiff Oncology : Investor Presentation - February 2021

Turning the Tide on Cancer

February 2021

Forward-Looking Statements

Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2019, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and we do not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Investment Highlights

3rd Generation, 1st-in-class,

Oral PLK1 Inhibitor

Onvansertib overcomes the shortcomings of prior PLK inhibitors:

• Highly selective for PLK1
• Orally administered
• 24-hourhalf-life
• Flexible dose and schedule

Specifically targets a known mechanism of cell division that is required for tumor cell viability

Preliminary clinical data demonstrate the safety, tolerability and efficacy of onvansertib in combination with SOC across multiple indications

Strong Lead Program in KRAS-mutated mCRC

Supported by compelling preliminary clinical data from a Phase 1b/2 trial showing a ten-foldimprovement in ORR compared to SOC

Preclinical data support:

• MOA of synthetic lethality between KRAS mutant mCRC and PLK1 inhibition
• Synergy with irinotecan and 5-FU

First Indication: 2nd line treatment in patients who have failed 1st line treatment with FOLFOX with/without bevacizumab

FDA Fast Track Designation

Diversified Pipeline Across

Numerous Cancers

Clinical data from ongoing trials support the use of onvansertib in combination regimens across Numerous aggressive cancers:

• mCRC Phase 1b/2 trial
• mCRPC Phase 2 trial
• PDAC Phase 2 trial
• AML Phase 2 trial

Expansion opportunities:

• Chronic myelomonocytic leukemia
• Triple negative breast cancer
• Lung cancer
• Ovarian cancer

Integrated Biomarker

Strategy

Circulating Tumor DNA: changes in KRAS mutational burden in blood are predictive of subsequent tumor shrinkage (mCRC)

Circulating Tumor Cells: changes are predictive of overcoming anti- androgen resistance (mCRPC)

Circulating Tumor DNA: changes are predictive of decreases in leukemic bone marrow cells (AML)

PLK: Polo-like Kinase; SOC: Standard-of-care; ORR: Overall response rate; MOA: Mechanism of action; mCRC: metastatic colorectal cancer;

mCRPC: metastatic castration resistant prostate cancer; PDAC: Pancreatic ductal adenocarcinoma; AML: Acute myeloid leukemia

2020 Corporation Presentation I 3

Experienced Management Team With Drug Development and Biomarker Technology Expertise

	Mark Erlander, PhD			Vicki Kelemen
	Chief Executive Officer			Chief Operating Officer

Brigitte Lindsay

Vice President of Finance

2020 Corporation Presentation I 4